Skip to main content
AVADEL PHARMACEUTICALS PLC logo

AVADEL PHARMACEUTICALS PLC — Investor Relations & Filings

Ticker · AVDL ISIN · IE00BDGMC594 US Manufacturing
Open in API
Filings indexed 1,009 across all filing types
Latest filing 2026-02-23 Regulatory Filings
Country US United States of America
Listing US AVDL

About AVADEL PHARMACEUTICALS PLC

https://www.avadel.com/

Avadel Pharmaceuticals PLC is a biopharmaceutical company focused on developing and commercializing therapies for sleep disorders, with a primary focus on narcolepsy. The company's lead product is LUMRYZ™, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Avadel's core strategy involves applying innovative solutions to drug development to address the challenges and unmet needs patients face with current treatment options, aiming to disrupt existing treatment paradigms.

Recent filings

Filing Released Lang Actions
15-12G - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
Regulatory Filings
2026-02-23 English
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
Director's Dealing
2026-02-18 English
S-8 POS Filing
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment to multiple Form S-8 Registration Statements filed with the SEC. It details the termination of registration of unsold or unissued shares under various stock option and share plans following the acquisition of Avadel Pharmaceuticals plc by Alkermes plc. The document is a regulatory filing related to securities registration and deregistration, specifically concerning share issuance plans and their termination. It is not a financial report, earnings release, or management discussion, nor is it a proxy, voting result, or capital change announcement. The document is a formal SEC filing that updates registration statements and terminates their effectiveness, fitting the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-12 English
4 Filing
Director's Dealing
2026-02-12 English
4 Filing
Director's Dealing
2026-02-12 English
S-8 POS Filing
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment to multiple Form S-8 Registration Statements filed with the SEC by Avadel Pharmaceuticals plc. It details the termination of registration of unsold or unissued shares under various stock option and share plans following the acquisition of the company by Alkermes plc. The document is a regulatory filing related to securities registration and deregistration, specifically amendments to registration statements, not a financial report, earnings release, or other report type. It does not contain financial statements or management discussion but is a formal SEC filing about registration status changes. Therefore, it fits best under Regulatory Filings (RNS). The document length is over 10,000 characters and contains detailed legal and regulatory information, confirming it is not a mere announcement but a substantive regulatory filing.
2026-02-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.